Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TRAF1: lord without a RING.

Juan M Zapata1, John C Reed

  • 1Burnham Institute, La Jolla, CA 92037, USA. jzapata@burnham.org

Science'S STKE : Signal Transduction Knowledge Environment
|May 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Community series in mouse models of B cell malignancies, volume II.

Frontiers in immunology·2024
Same author

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.

Science advances·2023
Same author

K63 ubiquitination in immune signaling.

Trends in immunology·2022
Same author

Editorial: Mouse Models of B Cell Malignancies.

Frontiers in immunology·2021
Same author

The <i>Traf2</i>DNx<i>BCL2-tg</i> Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.

Frontiers in immunology·2021
Same author

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.

Frontiers in immunology·2021
Same journal

Identification of redox-active cell-surface proteins by mechanism-based kinetic trapping.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Image correlation spectroscopy.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Studies of SARM1 uncover similarities between immune and neuronal responses to danger.

Science's STKE : signal transduction knowledge environment·2007
Same journal

A discrete signaling function for an inositol pyrophosphate.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Putting on the RITz.

Science's STKE : signal transduction knowledge environment·2007
Same journal

Type I interferons as anti-inflammatory mediators.

Science's STKE : signal transduction knowledge environment·2007
See all related articles

Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are adaptor proteins. TRAF1 acts as a negative regulator of TNF signaling, as shown by hyper-responsive T cells and increased skin necrosis in TRAF1-deficient mice.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Tumor necrosis factor (TNF) receptor-associated factors (TRAFs) are adaptor proteins crucial for cytokine signaling.
  • Six TRAF family members (TRAF1-6) exist in mammals, mediating signals from TNF-family receptors (TNFRs).
  • TRAF1 is unique, lacking a RING finger domain and exhibiting restricted expression in immune cells and epithelia.

Purpose of the Study:

  • To review current knowledge on TRAF1, emphasizing findings from TRAF1-deficient mice.
  • To explore the role of TRAF1 as a negative regulator of TNF-family receptor signaling.
  • To discuss the potential of TRAFs as drug discovery targets.

Main Methods:

  • Analysis of data from TRAF1-deficient (TRAF1(-/-)) mice.

Related Experiment Videos

  • In vitro assessment of T cell receptor (TCR)-dependent T cell proliferation.
  • In vivo evaluation of sensitivity to TNF-alpha-induced skin necrosis.

    • Main Results:

    • TRAF1-deficient T cells exhibit hyper-responsiveness to TNF-alpha.
    • Increased T cell proliferation rates were observed in TRAF1-deficient T cells in vitro.
    • TRAF1-deficient mice showed heightened sensitivity to TNF-alpha-induced skin necrosis in vivo.

    Conclusions:

    • TRAF1 functions as a negative regulator of signaling pathways initiated by certain TNF-family receptors.
    • TRAF1 deficiency leads to exaggerated responses to TNF-alpha.
    • TRAFs present both opportunities and challenges as targets for therapeutic drug development.